SciTech Development Announces First Patient Dosed in Phase 1 Clinical Trial of ST-001
SciTech Development Announces First Patient Dosed in Phase 1 Clinical Trial of ST-001This study is designed to evaluate ST-001 for the treatment of T-cell non-Hodgkin’s lymphoma (NHL). NEWS PROVIDED BY SciTech Development, LLC 20 Dec, 2023, 08:00 ET GROSSE POINTE, Mich., Dec. 20, 2023 /PRNewswire/ — SciTech Development (“SciTech” or the “Company”), a clinical-stage pharmaceutical…